https://www.linktr.ee/sudkrishnamurthy
newsroom.wakehealth.edu/news-release...
If you made it this far, thank you for reading! 😊
(7/7)
newsroom.wakehealth.edu/news-release...
If you made it this far, thank you for reading! 😊
(7/7)
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
(6/x)
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
(6/x)
See here for some coverage of our work: www.dailymail.co.uk/health/artic...
(5/x)
See here for some coverage of our work: www.dailymail.co.uk/health/artic...
(5/x)
(4/x)
(4/x)
First, we found that Black participants in the study faced a higher burden of place-based SDoH. 🗺️
Second, we found that these higher burdens of SDoH were associated with worse biomarker outcomes among Black participants.‼️
(3/x)
First, we found that Black participants in the study faced a higher burden of place-based SDoH. 🗺️
Second, we found that these higher burdens of SDoH were associated with worse biomarker outcomes among Black participants.‼️
(3/x)
The primary research question in the study was to examine the relationships of place-based SDoH with biomarkers of dementia.❓
(2/x)
The primary research question in the study was to examine the relationships of place-based SDoH with biomarkers of dementia.❓
(2/x)
(3/3)
(3/3)
(2/3)
(2/3)
Absolutely - this project wouldn't have happened without help from @dusetzinas.bsky.social and Shelley (who isn't on Bluesky yet)! Can't thank them both enough!😊
Absolutely - this project wouldn't have happened without help from @dusetzinas.bsky.social and Shelley (who isn't on Bluesky yet)! Can't thank them both enough!😊
(7/7)
(7/7)
And a special thanks to my mentor, sponsor, and friend in this work, @uressien.bsky.social, for giving me the opportunity to lead this project after we first discussed it back in 2022!
(6/x)
And a special thanks to my mentor, sponsor, and friend in this work, @uressien.bsky.social, for giving me the opportunity to lead this project after we first discussed it back in 2022!
(6/x)
(5/x)
(5/x)
In other words, although Black and Hispanic beneficiaries had lower rates of receipt of ERBB2/HER2-targeted therapies than white beneficiaries in 2010, this disparity was no longer seen in 2019.
(4/x)
In other words, although Black and Hispanic beneficiaries had lower rates of receipt of ERBB2/HER2-targeted therapies than white beneficiaries in 2010, this disparity was no longer seen in 2019.
(4/x)